SPIEF: Signing of an agreement of intent

The project partners are Russian pharmaceutical manufacturing company Avexima, national pharmaceutical distributor FC Grand Capital LLC and development partner Uspeshnye Investitsii LLC.

On an area of more than 25 hectares, the entire cycle from the development and production of medicines to their prompt delivery to medical institutions and pharmacies in the country is to be realised.

"The Yesipovo Pharmaceutical Cluster is a shining example of cooperation between government and business. The partnership helps not only to strengthen the position of the Russian pharmaceutical industry, but also solves social issues in terms of creating new workplaces and tax deductions at the regional level," said Denis Remenyako. - The Yesipovo Pharmaceutical Cluster will be home to high-tech production of the most popular groups of medicines, and we will start producing biotech products to treat oncological and infectious diseases. This would increase Russia's independence from imports. In addition, Yesipovo is also a platform where educational projects for young professionals can be implemented".

Two production and logistics complexes will be built to produce various types of products, including solid, soft and liquid sterile dosage forms, antibiotics and biotechnological preparations.
The estimated investment is RUB 6.5 billion.
The project will create 1,450 new workplaces as a result of the project.